Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential

被引：8
作者：
Wilson, Brooke E. [1 ,2 ]
Shen, Qiang [3 ]
Cescon, David W. [4 ,5 ]
Reedijk, Michael [4 ,5 ,6 ]
机构：
[1] Queens Univ, Dept Oncol, Kingston, ON, Canada
[2] Queens Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Hlth Network, Dept Surg Oncol, Toronto, ON, Canada
来源：
FRONTIERS IN GENETICS | 2023年 / 14卷
关键词：
triple negative breast cancer; IL1beta; immunotherapy; tumor microenvironment; inflammasome; TUMOR-INFILTRATING LYMPHOCYTES; CELL LUNG-CANCER; PHASE-III; INFLAMMATION; MACROPHAGES; MECHANISM; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY; CANAKINUMAB;
D O I：
10.3389/fgene.2023.1086163
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Triple negative breast cancer (TNBC) has poor prognosis when compared to other breast cancer subtypes. Despite pre-clinical data supporting an immune targeted approach for TNBCs, immunotherapy has failed to demonstrate the impressive responses seen in other solid tumor malignancies. Additional strategies to modify the tumor immune microenvironment and potentiate response to immunotherapy are needed. In this review, we summarise phase III data supporting the use of immunotherapy for TNBC. We discuss the role of IL-1 beta in tumorigenesis and summarize pre-clinical data supporting IL-1 beta inhibition as a potential therapeutic strategy in TNBC. Finally, we present current trials evaluating IL-1 beta in breast cancer and other solid tumor malignancies and discuss future studies that may provide a strong scientific rationale for the combination of IL-1 beta and immunotherapy in the neoadjuvant and metastatic setting for people with TNBC.
引用
收藏
页数：8
相关论文
共 66 条
  • [1] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    Adams, Sylvia
    Gray, Robert J.
    Demaria, Sandra
    Goldstein, Lori
    Perez, Edith A.
    Shulman, Lawrence N.
    Martino, Silvana
    Wang, Molin
    Jones, Vicky E.
    Saphner, Thomas J.
    Wolff, Antonio C.
    Wood, William C.
    Davidson, Nancy E.
    Sledge, George W.
    Sparano, Joseph A.
    Badve, Sunil S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 2959 - +
  • [2] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    Allison, Kimberly H.
    Hammond, M. Elizabeth H.
    Dowsett, Mitchell
    McKernin, Shannon E.
    Carey, Lisa A.
    Fitzgibbons, Patrick L.
    Hayes, Daniel F.
    Lakhani, Sunil R.
    Chavez-MacGregor, Mariana
    Perlmutter, Jane
    Perou, Charles M.
    Regan, Meredith M.
    Rimm, David L.
    Symmans, W. Fraser
    Torlakovic, Emina E.
    Varella, Leticia
    Viale, Giuseppe
    Weisberg, Tracey F.
    McShane, Lisa M.
    Wolff, Antonio C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) : 1346 - +
  • [3] IL-1 Family Members in Cancer; Two Sides to Every Story
    Baker, Kevin J.
    Houston, Aileen
    Brint, Elizabeth
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [4] Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
    Bjoern, Jon
    Nitschke, Nikolaj Juul
    Iversen, Trine Zeeberg
    Schmidt, Henrik
    Fode, Kirsten
    Svane, Inge Marie
    [J]. ONCOIMMUNOLOGY, 2016, 5 (04):
  • [5] Inflammasomes: mechanism of assembly, regulation and signalling
    Broz, Petr
    Dixit, Vishva M.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2016, 16 (07) : 407 - 420
  • [6] The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis
    Carmi, Yaron
    Voronov, Elena
    Dotan, Shahar
    Lahat, Nitza
    Rahat, Michal A.
    Fogel, Mina
    Huszar, Monika
    White, Malka R.
    Dinarello, Charles A.
    Apte, Ron N.
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 183 (07) : 4705 - 4714
  • [7] IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization
    Castano, Zafira
    San Juan, Beatriz P.
    Spiegel, Asaf
    Pant, Ayush
    DeCristo, Molly J.
    Laszewski, Tyler
    Ubellacker, Jessalyn M.
    Janssen, Susanne R.
    Dongre, Anushka
    Reinhardt, Ferenc
    Henderson, Ayana
    del Rio, Ana Garcia
    Gifford, Ann M.
    Herbert, Zachary T.
    Hutchinson, John N.
    Weinberg, Robert A.
    Chaffer, Christine L.
    McAllister, Sandra S.
    [J]. NATURE CELL BIOLOGY, 2018, 20 (09) : 1084 - +
  • [8] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    Cortes, J.
    Rugo, H. S.
    Cescon, D. W.
    Im, S-A
    Yusof, M. M.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V
    Pan, W.
    Schmid, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) : 217 - 226
  • [9] Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
    Coussens, Lisa M.
    Zitvogel, Laurence
    Palucka, A. Karolina
    [J]. SCIENCE, 2013, 339 (6117) : 286 - 291
  • [10] The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis
    Cunnane, G
    Madigan, A
    Murphy, E
    FitzGerald, O
    Bresnihan, B
    [J]. RHEUMATOLOGY, 2001, 40 (01) : 62 - 69
1234567